Methods of treating an inflammatory-related disease
View Patent ↗The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
1. A method of treating ulcerative colitis, which comprises administering to an animal in need of such treatment a compound of formula (IV)
wherein the compound is administered in an amount sufficient to treat ulcerative colitis by inhibiting pro-inflammatory cytokine expression and/or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.
2. The method according to claim 1 , wherein the animal is a human being.
3. The method according to claim 1 , wherein the compound is administered at a concentration sufficient to inhibit cytokine IL-1α, β, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-α, LT, LIF, Oncostatin, or IFNc1α, β, γ.
4. The method according to claim 1 , where the compound is administered at a concentration sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGFβ.
5. A method of treating ulcerative colitis, the method comprising administering to an animal in need of such treatment a compound of formula (IV)
wherein the compound is administered in an amount sufficient to treat ulcerative colitis.
6. The method according to claim 5 , wherein the compound is administered at a concentration sufficient to inhibit cytokine IL-1α, β, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-α, LT, LIF, Oncostatin, or IFNc1α, β, γ.
7. The method according to claim 5 , where the compound is administered at a concentration sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGFβ.